Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins - powder for solution for injection - 50 - other muscle relaxants, peripherally acting agents; botulinum toxin

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins - powder for solution for injection - 100 - other muscle relaxants, peripherally acting agents; botulinum toxin

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins - powder for solution for injection - 200 - other muscle relaxants, peripherally acting agents; botulinum toxin

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neurotoxin type a (150kd), free of complexing proteins - powder for solution for injection - 100 unit(s) - botulinum toxin

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

merz pharmaceuticals gmbh - clostridium botulinum neurotoxin type a (150kd), free of complexing proteins - powder for solution for injection - 50 unit(s) - botulinum toxin

Singapoo - Kiingereza - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - irinotecan hydrochloride trihydrate - injection, solution - irinotecan hydrochloride trihydrate 20.0 mg/ml

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - moxifloxacin hydrochloride, quantity: 1.74 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - moxifloxacin-baxter is indicated for treatment of adults who require initial i.v. therapy for the treatment of infections in the conditions: ? community acquired pneumonia (caused by susceptible organisms) ? acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics moxifloxacin-baxter is indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin-baxter may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - indium (111in) hydroxyquinoline, quantity: 0.01 microgram/ml (equivalent: indium (111in) chloride, qty 37 mbq/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; hepes; oxyquinoline; polysorbate 80 - for in vitro radiolabelling of separated leucocytes and platelets which are subsequently reinjected intravenously for investigative purposes using appropriate imaging/counting procedures.